Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma

NCT02690948 is registered in ClinicalTrials.gov with Anne Chang as lead sponsor.

NCT NCT02690948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02690948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
Lead sponsor
Anne Chang
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2016
Completion date
August 29, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin basal cell carcinoma